QM
BIO icon

QVIDTVM Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

QVIDTVM Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4M Sell
66,243
-17,489
-21% -$4.96M 25.39% 1
2026
Q1 		$23.3M Buy
83,732
+249
+0.3% +$71.7K 28.68% 1
2025
Q4 		$25.3M Sell
83,483
-42,997
-34% -$13.4M 28.62% 1
2025
Q3 		$35.5M Buy
126,480
+400
+0.3% +$109K 38.17% 2
2025
Q2 		$30.4M Sell
126,080
-120
-0.1% -$28.4K 30.47% 2
2025
Q1 		$30.7M Buy
126,200
+7,253
+6% +$2.18M 27.17% 2
2024
Q4 		$39.1M Sell
118,947
-6,991
-6% -$2.37M 31.47% 1
2024
Q3 		$42.1M Hold
125,938
– – 29.49% 1
2024
Q2 		$34.4M Hold
125,938
– – 27.51% 1
2024
Q1 		$43.6M Buy
125,938
+900
+0.7% +$296K 35.07% 1
2023
Q4 		$40.4M Buy
125,038
+55,867
+81% +$17.5M 34% 1
2023
Q3 		$24.8M Buy
+69,171
New +$26.7M 19.26% 3

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

QVIDTVM Management's BIO Position: Q2 2026 in Review

QVIDTVM Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 21% in Q2 2026, selling an estimated $4.96M and leaving 66,243 shares worth $19.4M. The position accounts for 25.39% of the portfolio, ranked #1.

QVIDTVM Management first reported a position in BIO in Q3 2023 and has held it in 12 quarters since. The position peaked at $43.6M in Q1 2024. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • QVIDTVM Management held 66,243 shares of Bio-Rad Laboratories Class A worth $19.4M as of Q2 2026.
  • QVIDTVM Management sold 17,489 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $4.96M.
  • Bio-Rad Laboratories Class A made up 25.39% of QVIDTVM Management's portfolio in Q2 2026, its #1 holding.
  • QVIDTVM Management first reported a position in Bio-Rad Laboratories Class A in Q3 2023 and has held it in 12 quarters since.
  • QVIDTVM Management's Bio-Rad Laboratories Class A position peaked at $43.6M in Q1 2024.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on QVIDTVM Management's 13F filing for Q2 2026, filed 13 Aug 2026.